The "chlamydial anomaly," first coined by James Moulder, describes the inability of researchers to detect or purify peptidoglycan (PG) from pathogenic Chlamydiae despite genetic and biochemical evidence and antibiotic susceptibility data that suggest its existence. We recently detected PG in Chlamydia trachomatis by a new metabolic cell wall labeling method, however efforts to purify PG from pathogenic Chlamydiae have remained unsuccessful. Pathogenic chlamydial species are known to activate nucleotide-binding oligomerization domain-containing protein 2 (NOD2) innate immune receptors by as yet uncharacterized ligands, which are presumed to be PG fragments (muramyl di-and tripeptides). We used the NOD2-dependent activation of NF-κB by C. trachomatis-infected cell lysates as a biomarker for the presence of PG fragments within specific lysate fractions. We designed a new method of muropeptide isolation consisting of a double filtration step coupled with reverse-phase HPLC fractionation of Chlamydia-infected HeLa cell lysates. Fractions that displayed NOD2 activity were analyzed by electrospray ionization mass spectrometry, confirming the presence of muramyl di-and tripeptides in Chlamydia-infected cell lysate fractions. Moreover, the mass spectrometry data of large muropeptide fragments provided evidence that transpeptidation and transglycosylation reactions occur in pathogenic Chlamydiae. These results reveal the composition of chlamydial PG and disprove the "glycanless peptidoglycan" hypothesis.
T he existence of peptidoglycan (PG) in pathogenic Chlamydiae has long been debated. Although genetic analysis and antibiotic susceptibility indicate the presence of PG in Chlamydia (1-3), all attempts to detect and purify PG have been unsuccessful (4) (5) (6) (7) , resulting in the paradox known as the "chlamydial anomaly" (8) . Ghuysen and Goffin (9) hypothesized that Chlamydia might synthesize a "glycanless PG" based on the observation that the Chlamydia genome encodes two high molecular mass penicillin-binding proteins (PBPs) that are devoid of transglycosylase activity, which is essential for elongation of the glycan chain of classical PG. Besides doubts about the presence of a glycan backbone in chlamydial PG, there are ambiguities about the sequence of the stem peptide. Patin et al. (10) suggested glycine, L-serine, or L-alanine as the possible first amino acid residue of the chlamydial PG stem. Resolution of the chlamydial anomaly by purification and structural characterization of chlamydial PG will have a profound impact not only on chlamydial biology but also on shaping our understanding of the host innate immune responses. Many pathogenic Chlamydia species activate the nucleotide-binding oligomerization domain-containing protein (NOD) family of innate receptors during infection (11) (12) (13) (14) . The inflammatory potential of chlamydial PG would vary depending on the composition of both the sugar backbone as well as the stem peptide sequence. NOD2 receptors recognize the sugar backbone of PG, and therefore, a "glycanless chlamydial PG" may not activate NOD2 receptors and fail to induce an inflammatory response (15) .
In a similar fashion, variations in the stem peptide sequence would alter NOD1 receptor recognition and the host inflammatory response (15) . Because two serious inflammatory consequences of Chlamydia trachomatis infection are pelvic inflammatory disease and trachoma, the exact molecular identity of chlamydial PG has high biological relevance and is essential to identifying the role PG plays in the induction of inflammation in these disease states.
Pilhofer et al. (16) recently succeeded in purifying PG sacculi from an environmental Protochlamydia species but were unable to detect or purify PG from Simkania, a distinct environmental species, by standard PG sacculi purification protocols. Because pathogenic Chlamydiae are more similar to Simkania (17) than to Protochlamydia in the content of PG biosynthetic pathway genes, Pilhofer et al. speculated that pathogenic Chlamydiae could be devoid of PG sacculi similar to Simkania (16). We recently demonstrated the presence of PG in C. trachomatis by a new metabolic cell wall labeling method (18) and observed that chlamydial PG does not appear to form a sacculus but is present in a ring-like structure at the apparent cell division plane. Given the absence of a PG sacculus, we hypothesized that purification of PG from pathogenic Chlamydiae required a technique other than the standard PG sacculi isolation method to succeed. In addition, previous unsuccessful searches for PG in pathogenic Chlamydiae focused on
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The existence of peptidoglycan (PG) in pathogenic Chlamydiae is supported by genetic data and antibiotic susceptibility, but the failure to isolate PG from pathogenic Chlamydiae has led to the "chlamydial anomaly." Moreover, the lack of a transglycosylase domain in some Chlamydia penicillin-binding proteins suggests that Chlamydiae may possess a "glycanless PG." We successfully enriched Chlamydia muropeptides from Chlamydia-infected cell lysates using nucleotide-binding oligomerization domain-containing protein 2 (NOD2)-dependent NF-κB activation as a biomarker for the presence of PG fragments in specific fractions. Mass spectrometry analysis indicated the presence of chlamydial muropeptides and classified chlamydial PG as type A1γ in the Schleifer and Kandler classification. This study disproves the glycanless PG hypothesis and is, to our knowledge, the first structural confirmation of chlamydial PG in pathogenic species.
purification of the developmental forms of Chlamydia-that is, elementary bodies (EBs) or reticulate bodies (RBs) (4, 16, 19) -as opposed to sampling intracellular Chlamydia directly from infected cells. Therefore, we saw the need to develop a new PG isolation technique for pathogenic Chlamydiae.
PG fragments induce NF-κB signaling in infected cells through the cognate cytoplasmic NOD receptors (15, 20, 21) , and many pathogenic Chlamydia species activate NOD receptors during infection (11) (12) (13) (14) . The identities of Chlamydia NOD ligands are unknown but are presumed to be PG constituents-that is, muramyl dipeptide (MDP) and muramyl tripeptide (MTP). Our strategy to purify PG fragments from pathogenic Chlamydiae used a reporter cell line to detect NOD2-dependent activation of NF-κB. By testing individual chromatographic fractions of C. trachomatis-infected cell lysates for the ability to activate NOD2, we identified those that contain immunostimulatory PG fragments. Electrospray ionization (ESI) mass spectrometry was used to determine the molecular identity of NOD2 ligands in these fractions. Our results showed that fractions that activated NOD2 were enriched in the canonical NOD2 ligand MDP, as well as MTP and larger PG constituents.
Larger PG fragments present in the activating fractions provided evidence for cross-links formed between PG stem peptide chains and for glycan chains composed of N-acetylmuramic acid (MurNAc) and N-acetylglucosamine (GlcNAc) saccharides. Our molecular detection of chlamydial PG fragments resolves the much-debated chlamydial anomaly, disproves the glycanless PG hypothesis regarding pathogenic Chlamydiae, and identifies chlamydial MDP as a ligand for the host innate immune receptor NOD2.
Results
Chlamydia-Infected HeLa Cell Lysates Specifically Induce NOD2-Dependent NF-κB Activity. Multiple studies have shown that intracellular pathogenic Chlamydiae induce NF-κB signaling by activating NOD2 receptors (11) (12) (13) (14) . To isolate chlamydial ligand(s) that activate NOD2 (i.e., MDP), HeLa cells were infected with C. trachomatis L2 serovar for 2 h and cell lysates were harvested at various time points throughout the developmental cycle (2, 8, 18, 28 , and 38 h) and filtered first through a 0.2-μm filter and then through a 3-kDa centrifugal filter. When added (extracellularly) to HEK-Blue NOD2 secreted alkaline phosphatase (SEAP) reporter cell lines, the 3-kDa centrifugal filter flow-through from Chlamydia-infected cells at 18 h postinfection (PI) induced maximum NF-κB activity compared with earlier or later time points (Fig. 1A) . Because peak induction of NOD2 activity was found at 18 h PI, all experiments were performed with cell lysates harvested at 18 h PI. NF-κB induction from infected cell lysates was significantly higher than mock-infected controls (P < 0.005 unpaired t test), and the activity was NOD2-dependent in HEK-Blue NOD2 cells as NF-κB induction by infected cell lysates was minimal in HEK-Blue Null2 cells that are devoid of the NOD2 receptor (Fig. 1B) . Heat and RNase A treatments of cell lysates had minimal effect on the infected sample's ability to induce NF-κB activity (Fig. S1 ), indicating that the NOD2 ligand is heat stable and excluding RNA as a possible NOD2 chlamydial ligand. Treatment with inhibitors of PG biosynthesis such as D-cycloserine (DCS) and ampicillin significantly enhanced NOD2-dependent activity of infected cell lysates over infected but untreated cell lysates (P < 0.005 and P < 0.01, respectively, unpaired t test), strongly suggesting that the nature of the NOD2 ligand in infected lysates could be a muropeptide(s) (Fig. 1B) . + anhydro MTP (anhyrdo N-acetyl muramic acid-alanyl-glutamyl-diaminopimelic acid or anhydro MurNAc-Ala-Glu-DAP), was detected. The identity of this ion was confirmed by MS/MS analysis (Fig. S2) . Detection of Shigella anhydro MTP validated our muropeptide isolation method by cell lysate fractionation and served as a positive control in our search for chlamydial PG fragments. MS/MS spectra of the two synthetic ligands ( + ion of MDP, present exclusively in Chlamydia-infected lysates. MS/MS spectral analysis ( Fig. 2A ) of this ion confirmed it to be MDP (MurNAc-Ala-Glu). We also confirmed the presence of MTP (MurNAc-Ala-Glu-DAP) in infected lysates by MS/MS analysis of an ion of 666.2 m/z (Fig. 2B ). The quantity of MTP was very low in infected samples, which made consistent detection of this species difficult by MS/MS. Moreover, the sub 3 kDa lysates were very complex, resulting in substantial background that obscured MS/MS detection of lowabundance MTP species.
HPLC Fractionation of Cell Lysates to Enrich for NOD2-Stimulating
Activity. To further purify NOD2 ligands from the highly complex sub 3 kDa lysate, we fractionated the lysates by HPLC. The sub Chlamydia-infected and mock-infected HeLa cell lysates were harvested at various time points during the developmental cycle, and their ability to induce NOD2-dependent NF-κB activity was assessed in a HEK-Blue NOD2 reporter cell line carrying a NF-κB-inducible alkaline phosphatase reporter gene. Peak NOD2-dependent activity was observed for Chlamydia-infected cell lysates harvested at 18 h PI. (B) The ability of Chlamydia-infected HeLa cell lysates harvested at 18 h PI to induce NF-κB activity was tested in HEK-Blue cell lines expressing (gray bars) or devoid of (white bars) NOD2 innate immune receptors and carrying a NF-κB-inducible alkaline phosphatase reporter gene. Alkaline phosphatase activity was measured at an OD of 650 nm following addition of infected and mock-infected cell lysates. Chlamydia-infected cell lysates induced higher NF-κB activity over mock-infected cell lysates in a NOD2-dependent manner. Treatment with PG synthesis inhibitors ampicillin (Amp, 1 μg/mL) and DCS (30 μg/mL) greatly enhanced the ability of Chlamydia-infected cell lysates to induce NF-κB activity in a NOD2-dependent manner over the corresponding untreated infected cell lysates. **P < 0.01, ***P < 0.005 unpaired t test; ns, nonsignificant. OD 650 values are mean ± SEM; n = 3.
3 kDa lysates were fractionated on a reverse-phase C18 column, and 1.2-mL fractions were collected each minute (designated F1 to F20) while UV absorbance was monitored at 215 nm. The UV chromatograms of the eluted fractions from the infected cell lysates looked similar to those of the mock-infected cell lysates; the chromatogram of the infected lysate is shown in Fig. S4 . The ability of each fraction (F1 to F20) to induce NOD2-dependent NF-κB activity was tested on HEK-Blue NOD2 SEAP reporter cells. The fraction from infected lysates collected in the second minute (F2) specifically induced NOD2 activity compared with the corresponding mock-infected F2 fraction (Fig. 3) . Shigella-infected HeLa cell lysates used as a positive control showed an F2 fraction that retained most of the NOD2 activity, similar to the Chlamydiainfected fraction. MDP and MTP synthetic muropeptides used as positive controls also eluted from the C18 column in the F2 fraction ( Fig. S4 A and B) . These results suggest that NOD2-activating ligand(s) found in the Chlamydia F2 fraction have C18 column interacting properties (i.e., they are highly hydrophilic and have limited affinity for the hydrophobic C18 column) similar to those of the activating fraction from Shigella-infected cells and synthetic MDP and MTP.
Structural Evidence for Transpeptidation and Transglycosylation
Reactions in Formation of Chlamydial PG. The NOD2 activation-based screening assay yielded a fraction that coeluted with the NOD2 ligands MDP and MTP, which were identified in Chlamydia-infected lysates. However, these muropeptides could potentially originate from early PG precursors such as Park's nucleotide, lipid I, or lipid II. To determine if these chlamydial muramyl peptides could be constituents of polymerized PG, we used the information-dependent acquisition (IDA) method of mass spectrometry (22) to identify larger muropeptide fragments (mass-to-charge ratios from greater than 600 up to 1,800) that could be part of polymerized PG. The criteria to identify these larger fragments included presence solely in infected lysates and sensitivity to ampicillin treatment. We identified two prominent doubly charged ions of 653.0 and 763.9 m/z (eluting at 8.8 min) (Fig. S5A) , the abundance of which was sensitive to ampicillin, a known inhibitor of transpeptidation and carboxypeptidation reactions (Fig. S5B) . Because these fragments could be generated by mechanical shearing, in-source fragmentation, or digestion by bacterial or eukaryotic enzymes, their nature is difficult to predict. To verify the identity of the fragments as PG constituents and solve their structure, we identified peaks in the MS/MS spectra separated by mass differences that are characteristic of fragmentation of the stem peptide of PG (129 amu, loss of glutamate; 172 amu, loss of DAP; and 71 amu, loss of alanine). The MS/MS analysis of the doubly charged ion of 653.0 m/z was interpreted to yield a structure that provides evidence for transpeptidation and carboxypeptidation reactions in chlamydial PG, as the structure includes two DAP residues linked by an alanine residue (Fig. 4 A  and B) . Interestingly, the first residue in the peptide of this fragment was glycine. The chlamydial MurC enzyme, which ligates the first amino acid of the stem peptide to MurNAc, has been shown to lack selectivity for alanine over glycine or serine (23) . Moreover, chlamydial MurE and MurF (which add subsequent amino acids to the growing stem peptide) are able to use glycine-containing peptides as substrate (10, 24) . These observations suggest that C. trachomatis PG may contain a mixture of alanine and glycine as the first amino acid in the stem peptide. MS/MS analysis of the second most prominent ion, 763.9 m/z, which shared many of the fragments seen from the 653.0 m/z ion, revealed the presence of two MurNAc sugars joined by a GlcNAc sugar (Fig. S6 A and B) . The chlamydial PG is classified as A1γ type PG (25) based on the molecular identity of the sugars, stem peptides, and the crosslinks detected in our study. The detection of these muropeptides exclusively in the infected cell lysate fraction conclusively shows that pathogenic Chlamydiae possess a polymerized PG containing both cross-linked stem peptides and glycan chains composed of MurNAc/GlcNAc residues.
Discussion
Although we recently demonstrated the presence of PG rings in pathogenic Chlamydiae by a metabolic cell wall labeling method, the molecular identity of chlamydial PG remained unknown. The failure of previous attempts to isolate chlamydial PG could possibly be due to the kinetics of PG production during the developmental cycle. Most previous studies focused on the isolation of PG sacculi from purified EBs or RBs at early or late stages of the developmental cycle. The current study indicated that PG production is minimal or absent at the start as well as at the conclusion of the developmental cycle and peak production occurs 18 h PI. These findings are consistent with the results of our labeling studies (18) , in which PG ring formation was observed at 18 h PI, localized only to the apparent cell division plane, and did not form a sacculus around the bacterium. Our success in detecting chlamydial muropeptides in this study was largely due to our use of infected cell lysates (instead of purified bacteria), selection of the time point with maximal muropeptide abundance (18 h PI), fractionating the lysates from potential PG degrading host and bacterial enzymes (3 kDa cutoff), and the greatly increased sensitivity of our muropeptide detection approach compared with conventional methods. We used NOD2 receptor activation by Chlamydia-infected cell lysates as a reporter for the presence of muropeptide ligands in lysate fractions. The typical ligands for NOD2 activation are muropeptides, but instances of viral RNA-induced NOD2 activation have been reported (26) . RNase A and heat treatment of cell lysates had little effect on NOD2 activation and thus ruled out RNA and heat-labile proteins as possible NOD2 ligands. We were able to confirm the presence of MDP and MTP in the infected cell lysate fractions that retained NOD2 activity. The identification of MTP allowed us to determine that DAP is the third residue of the stem peptide. Although initial annotation of the Chlamydia genome showed only an incomplete pathway for the synthesis of DAP (3, 6) , subsequent studies from our laboratory showed that Chlamydia can synthesize DAP by use of a previously unidentified aminotransferase that completes the pathway (27) . Thus, our structural data confirm that Chlamydia uses DAP as a component of the PG stem peptide. Although we did not include a PG digestion step in our Fig. 3 . NOD2 stimulating activity of F2 fraction of Chlamydia-infected cells collected from a reverse-phase C18 HPLC column. HPLC fractionation was performed, and 1.2-mL fractions were collected every minute. Mock-infected cell lysates were also fractionated, and NOD2 activities induced by them were considered as background. NOD2-induced NF-κB activity (measured at OD 650 ) for the various fractions collected from Chlamydia-infected (gray bar) or mock-infected lysates (open bar) was tested in HEK-Blue NOD2 cell lines as in Fig. 1 . MDP (positive) and Tri-DAP (L-Ala-γ-D-Glu-mDAP) (negative) control ligands were used at 1 μg/mL. ***P < 0.005 unpaired t test. OD 650 values are mean ± SEM; n = 3. isolation methodology, we detected free muropeptides (i.e., MDP and MTP) in NOD2-activating cell lysates. We suggest that host and bacterial PG degrading enzymes present during the process of lysate preparation would be capable of releasing free muropeptides.
NF-κB activation (OD 650)
In our previous study (18) , we showed evidence that suggested that both transglycosylation and transpeptidation occur in pathogenic chlamydial PG. The labeled annular PG structures are sensitive to lysozyme treatment and removal of the peptide-specific label by lysozyme, which targets the 1,4-beta-linkages between MurNAc and GlcNAc, suggesting that the labeled peptide is, in fact, incorporated into PG. We also demonstrated differential labeling using two distinct probes [ethynyl-D-alanyl-D-alanine (EDA-DA) and D-alanyl-ethynyl-D-alanine (DA-EDA)] in the presence or absence of ampicillin, an inhibitor of transpeptidation and carboxypeptidation. These observations showed that the di-peptide probes are incorporated into PG and are suitable substrates for transpeptidation/carboxypeptidation reactions. Here, we used mass spectrometry to confirm that transglycosylation and transpeptidation reactions contribute to synthesis of chlamydial PG. Larger muropeptide fragments that contain two MurNAc sugars and a GlcNAc sugar, along with a DAP residue linked by alanine with another DAP residue, serve as evidence that the muropeptides we detected polymerize to form a glycan chain composed of MurNAc/GlcNAc residues with cross-linking between peptide chains.
Although MS/MS data do not reveal the stereoisomeric state of amino acids in the stem peptide, we were able to deduce the chlamydial PG structure to be GlcNAc-MurNAc with a L-Ala/Gly-D-Glu-meso-DAP-D-Ala stem peptide. This conclusion is based on the following observations. MDP detection by (24) and UDP-MurNAc-L-Ala/Gly-D-Glu-meso-DAP (10) as substrates, respectively. Variability in the first position amino acid of the PG stem peptide has been reported in other bacteria (29) (30) (31) , and our results suggest the coexistence of alanine-and glycine-containing forms. Our previous studies (18) support the D-stereoisomer chemistry for the fourth and fifth alanines of the stem peptide. Hence, the data in our present study plus the above cited reports lead us to conclude that chlamydial PG is of a conventional Gram-negative PG structure, the same PG type (A1γ) found in Escherichia coli.
A limitation of our muropeptide isolation method coupled with the NOD2 screening method is that it selects for muropeptide fragments that are NOD2 agonists. Because the size cutoff we used for muropeptide isolation was 3 kDa, PG crosslinked fragments greater than 3 kDa could not be studied. Other limitations include that the search for the presence of novel modified PGs that are not NOD2 ligands could not be performed easily and that the IDA analysis only selected ions of high abundance. If novel modified PG exists at a low level, then it becomes very difficult to identify such PG fragments without a selective screening method.
One particularly interesting finding was that ampicillin, which inhibits PBPs and directly blocks PG cross-linking, and DCS, which inhibits alanine racemase and D-alanine:D-alanine ligase and indirectly blocks PG cross-linking, enhanced Chlamydia-induced NOD2 activity. In addition to the accumulation of PG precursors, we also considered muropeptide modification as a possible explanation for this increased activity. DCS treatment of Mycobacterium tuberculosis enhances glycolation of muropeptides mediated by NamH (32) . Glycolated muropeptides from M. tuberculosis are highly potent in activating NOD2 receptors compared with their unmodified muropeptides (33) . However, the Chlamydia genome does not encode a NamH homolog, and we found no evidence of muropeptide glycolyation in DCS-treated Chlamydia-infected cell lysates. The molecular basis of enhanced NOD2 activation by ampicillin and DCS-treated Chlamydia-infected cell lysates is currently under investigation. Because ampicillin and DCS treatments enhance the inflammatory potential of Chlamydia lysates, it would be interesting to determine the correlation of inflammatory markers in Chlamydia-infected patients who are treated with cell wall synthesis-inhibiting antibiotics. The protein synthesis inhibitors azithromycin and doxycycline are the preferred drugs to treat Chlamydia genital infections. By contrast, patients infected with Neisseria gonorrheae are generally treated with third-generation cephalosporins, which are cell wallacting antibiotics. An estimated 50-70% of individuals who are infected with N. gonorrheae are coinfected with Chlamydia (34-36). Thus, antigonococcal treatment with PG synthesistargeting drugs may exacerbate Chlamydia PG-induced inflammation in coinfected patients.
We cannot exclude the possibility of PG modification, especially in light of the DCS-induced enhancement of NOD2 activity. It is unclear whether pathogenic Chlamydiae have modified PG similar to that of environmental Chlamydiae, which have additional 129 and 203 mass units on virtually all of the PG monomers (16) . However, we could find no evidence of these modified PG fragments in pathogenic Chlamydia-infected cell lysates. Chlamydia muropeptide isolation from infected HeLa cell lysates suggests that NOD2 ligands can translocate from the inclusion membrane and activate the cytoplasmic NOD receptor in infected cells. Future studies will characterize the mechanism of chlamydial PG fragment translocation and activation of NOD receptors as well as the nature of inflammation induced by chlamydial PG and its importance in Chlamydia pathogenesis.
In summary, our study is the first, to our knowledge, to detect pathogenic chlamydial muropeptides by mass spectrometry. Chlamydial PG fragments specifically activate NOD2 receptors and induce inflammation that is enhanced by treatment with cell wallacting antibiotics. The chlamydial PG was determined to be of type A1γ chemotype and the muropeptides were unmodified. The detection of chlamydial PG disproved the glycanless PG hypothesis and resolved the long-standing chlamydial anomaly.
Materials and Methods
Preparation of Cell Lysates. HeLa cells were mock-infected or infected with C. trachomatis serovar L2 (37) at a multiplicity of infection of 1 for 2 h at 37°C in 5% (vol/vol) CO 2 with rocking. Infection medium was replaced with DMEM and heat-inactivated FBS [10% (vol/vol)], and cells were incubated up to 38 h. Cells were harvested with glass beads and resuspended in DMEM. The harvested HeLa cells were sonicated using an Ultrasonic processor (GE 100) at 40 A with 1-min pulses repeated five times. The cell lysates were centrifuged at 4,000 × g for 5 min at 37°C to remove cell debris. The supernatant was processed further for PG isolation by a double filtration method followed by fractionation of the filtrates by HPLC.
Muropeptide Isolation Method-Double Filtration
Step. Cell lysates were filter sterilized through 0.2-μm filters (Nalgene 5240020). Filter-sterilized cell lysates were further passed through 3-kDa centrifugal filters (Amicon UFC900324) at 4,000 × g for 1 h at 37°C to obtain flow-through fractions that would contain PG fragments (the expected size of muropeptides that activate NOD2 receptors is <2 kDa). Flow-through fractions from the 3-kDa centrifugal filters were heat inactivated at 95°C for 6 min and tested for NOD2 activity using a HEK NOD reporter cell line (38) . The flow-through was either analyzed by ESI mass spectrometry for molecular identification of muropeptides or further fractionated through reverse-phase HPLC to enrich the NOD2 ligands.
HPLC Purification. Flow-through fractions were concentrated 10-fold and fractionated by HPLC. For HPLC analysis, we ran an isocratic method using 5% acetonitrile in 95% water containing 0.12% trifluoroacetic acid as eluent for 20 min on a Vydac ODS/C18 column (4.6 mm × 150 mm; 5 μm, 300 Å particle beads W.R. Grace 218TP5415) at 30°C using a flow rate of 1.2 mL/min. UV detection was carried out at 215 nm.
NF-κB Reporter Assay. HEK cells expressing the NOD2 receptor and carrying the NF-κB SEAP reporter gene (Invivogen) were used according to the manufacturer's instructions to assess the NF-κB stimulatory property of the various cell lysate fractions and eluted fractions collected from the reverse-phase C18 HPLC column. Briefly, 20 μL of cell lysate fractions from both Chlamydiainfected as well as mock-infected HeLa cells were added to 5 × 10 4 HEK-Blue NOD2 or Null2 cells in 96-well plates and incubated for 24 h at 37°C (total reaction volume, 200 μL per well). For SEAP detection, 20 μL of supernatant from lysate fraction-treated wells was added to 180 μL of QUANTI-blue substrate (Invivogen) in another 96-well microtiter plate. Supernatants from untreated or uninfected cells were used as negative controls. The reaction was incubated at 37°C overnight, and SEAP activity was assessed by reading OD at 650 nm.
LCMS. Liquid chromatography and mass spectrometry (LCMS) experiments were performed on an Agilent 1200 Series liquid chromatography system coupled to an AB Sciex Q-Trap 4000 mass spectrometer with a Turbo V ESI source. Chromatographic separation and mass spectrometry conditions are described in SI Materials and Methods.
